PROM1 and peripheral arterial disease: Thus, Ben Zadok et al. [206] showed that the 3-months treatment with PCSK9i, reduced the lipidic levels and increased cEPCs number (CD34+ KDR+/CD133+KDR+) in CAD and PAD patients (10% of the patients suffered DM), and improved the in vitro colony-forming ability and viability of cEPCs.